Quintiles has launched a new continuous glucose monitoring service that combines wearable technology with therapeutics and analytics to help enhance the efficiency and quality of diabetes-focused clinical trials.

When used in clinical research, the new  offering will provide investigators with access to a myriad of customized data analytics and performance reports through the Quintiles Infosario technology platform.

The optimized glycemic data sets can be analyzed more efficiently to uncover trends such as non-compliance and potential safety triggers faster than traditional diabetes monitoring models. In addition, staff from the company will provide support to help drive smarter protocol design and enhance patient compliance.

Through the offering, continuous glucose measurements will be captured by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day.

In the clinical trial setting, comprehensive and timely glucose visibility has the potential to improve patient safety, accelerate clinical development and provide a basis for differentiated claims, according to the company.

“According to the International Diabetes Federation (IDF), every six seconds, a person dies from diabetes-related causes and almost half of those deaths are people under the age of 60,” Margaret Keegan, president of data sciences, safety and regulatory services at Quintiles, said. “With diabetes diagnoses on the rise, the need for innovative and accessible treatments also increases.”